This is what you need to know about cholesterol – and how it impacts your health - Experts say not all cholesterol is bad; in ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Although cholesterol and TG serve several important functions within the body, they are insoluble particles and must be packaged into lipoproteins in order to circulate in the plasma, from sites ...

LDL levels below 70 mg/dL are tied to a lower risk of developing dementia in general and Alzheimer’s disease-related dementia ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.